Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07284979

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Led by Kailera · Updated on 2026-04-30

1200

Participants Needed

32

Research Sites

119 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

CONDITIONS

Official Title

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • BMI 35 kilograms per square meter or higher
  • History of at least 1 unsuccessful attempt to lose weight with diet and exercise within the prior 6 months
Not Eligible

You will not qualify if you...

  • Current diagnosis or history of diabetes mellitus
  • Started medications within 3 months prior to Screening that may cause significant weight gain, including tricyclic antidepressants, atypical antipsychotics, and mood stabilizers
  • Unstable weight with a change exceeding 5% in the 3 months prior to Screening
  • Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer
  • Uncontrolled hypertension or unstable cardiovascular disease
  • History of chronic or acute pancreatitis
  • Known clinically significant gastric-emptying abnormality or chronic treatment with medications affecting gastrointestinal motility
  • History of suicide attempt
  • History of significant active or unstable Major Depressive Disorder or other severe psychiatric disorder
  • Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonists, GLP-1/GIP, or glucagon receptor agonists within 3 months prior to Screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 32 locations

1

Kailera Clinical Site

Glendale, Arizona, United States, 85308

Actively Recruiting

2

Kailera Clinical Site

Phoenix, Arizona, United States, 85012

Actively Recruiting

3

Kailera Clinical Site

Little Rock, Arkansas, United States, 72205

Actively Recruiting

4

Kailera Clinical Site

Northridge, California, United States, 91325

Actively Recruiting

5

Kailera Clinical Site

Oceanside, California, United States, 92058

Actively Recruiting

6

Kailera Clinical Site

Hamden, Connecticut, United States, 06517

Actively Recruiting

7

Kailera Clinical Site

Stamford, Connecticut, United States, 06905

Actively Recruiting

8

Kailera Clinical Site

Orange City, Florida, United States, 32763

Actively Recruiting

9

Kailera Clinical Site

Albany, Georgia, United States, 31707

Actively Recruiting

10

Kailera Clinical Site

Chicago, Illinois, United States, 60640

Actively Recruiting

11

Kailera Clinical Site

Newton, Kansas, United States, 67114

Actively Recruiting

12

Kailera Clinical Site

Shreveport, Louisiana, United States, 71105

Actively Recruiting

13

Kailera Clinical Site

Farmington Hills, Michigan, United States, 48334

Actively Recruiting

14

Kailera Clinical Site

Missoula, Montana, United States, 59804

Actively Recruiting

15

Kailera Clinical Site

Las Vegas, Nevada, United States, 89148

Actively Recruiting

16

Kailera Clinical Site

Albany, New York, United States, 12203

Actively Recruiting

17

Kailera Clinical Site

Morehead City, North Carolina, United States, 28557

Actively Recruiting

18

Kailera Clinical Site

Norman, Oklahoma, United States, 73069

Actively Recruiting

19

Kailera Clinical Site

East Greenwich, Rhode Island, United States, 02818

Actively Recruiting

20

Kailera Clinical Site

North Charleston, South Carolina, United States, 29405

Actively Recruiting

21

Kailera Clinical Site

Spartanburg, South Carolina, United States, 29303

Actively Recruiting

22

Kailera Clinical Site

Brownsville, Texas, United States, 78526

Actively Recruiting

23

Kailera Clinical Site

San Antonio, Texas, United States, 78229

Actively Recruiting

24

Kailera Clinical Site

Manassas, Virginia, United States, 20110

Actively Recruiting

25

Kailera Clinical Site

Richmond, Virginia, United States, 23236

Actively Recruiting

26

Kailera Clinical Site

Bruce, Australian Capital Territory, Australia, 2617

Actively Recruiting

27

Kailera Clinical Site

Blacktown, New South Wales, Australia, 2148

Actively Recruiting

28

Kailera Clinical Site

Kanwal, New South Wales, Australia, 2259

Actively Recruiting

29

Kailera Clinical Site

Herston, Queensland, Australia, 4006

Actively Recruiting

30

Kailera Clinical Site

Morayfield, Queensland, Australia, 4506

Actively Recruiting

31

Kailera Clinical Site

South Brisbane, Queensland, Australia, 4101

Actively Recruiting

32

Kailera Clinical Site

Camberwell, Victoria, Australia, 3124

Actively Recruiting

Loading map...

Research Team

K

Kailera Therapeutics, Inc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here